Drug Trial Radar · NCT07054684
Study of BHV-1400 in IgA Nephropathy
Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Jul 30, 2025
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Biohaven Therapeutics Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
Conditions
- IgA Nephropathy
Interventions
BHV-1400Drug
BHV-1400 is delivered subcutaneously (SC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Serious AEs (SAEs), AEs leading to discontinuation, deathsTime frame: Up to 1 year
- Number of participants with Grade 3-4 treatment-emergent laboratory abnormalitiesTime frame: Up to 1 year
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
Site-001
Farmington, Connecticut · Recruiting
Site-003
Miami Lakes, Florida · Recruiting
Site-011
Miami Lakes, Florida · Recruiting
Site-013
Orlando, Florida · Recruiting
Site-005
Pembroke Pines, Florida · Recruiting
Site-008
Lawrenceville, Georgia · Recruiting
Site-009
Hinsdale, Illinois · Recruiting
Site-012
Indianapolis, Indiana · Recruiting
Site-015
Shelby, Michigan · Recruiting
Site-006
Chesterfield, Missouri · Recruiting
Site-002
Dakota Dunes, South Dakota · Recruiting
Site-014
Houston, Texas · Recruiting
Site-004
Houston, Texas · Recruiting
Site-016
Salt Lake City, Utah · Recruiting
Site-007
Leicester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.